BPL-003 (mebufotenin benzoate) vs VLS-01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
BPL-003 (mebufotenin benzoate)
Developed by AtaiBeckley Inc. and partners
NCT05870540 · Phase 2 · completed
The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT05660642 (registry estimate)
Reported efficacy
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) (4 weeks): MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). (met)
Result source: NCT05870540
VLS-01
Developed by AtaiBeckley Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BPL-003 (mebufotenin benzoate) | VLS-01 |
|---|---|---|
| MADRS, change (acute) | -11.1 vs -5.8avs 0.3 mg comparator armNCT058705401 other result
| —Not reported |
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- BPL-003 (mebufotenin benzoate)
- -11.1 vs -5.8avs 0.3 mg comparator armNCT05870540
1 other result
- -12.1 vs -5.8 NCT05870540
- VLS-01
- —Not reported
CGI-S, change (acute)
- BPL-003 (mebufotenin benzoate)
- —Not reported
- VLS-01
- —Not reported
MADRS response
- BPL-003 (mebufotenin benzoate)
- —Not reported
- VLS-01
- —Not reported
MADRS remission
- BPL-003 (mebufotenin benzoate)
- —Not reported
- VLS-01
- —Not reported
Relapse (% of patients)
- BPL-003 (mebufotenin benzoate)
- —Not reported
- VLS-01
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
VLS-01: no structured comparison results are available for Major Depressive Disorder.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
BPL-003 (mebufotenin benzoate)
show 1 more result
Treatment-Resistant Depression
Shared mechanism: 5-HT2A receptor · full Treatment-Resistant Depression pipeline
BPL-003 (mebufotenin benzoate)
Developed by AtaiBeckley Inc. and partners
NCT05870540 · Phase 2 · completed
The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT05660642 (registry estimate)
Reported efficacy
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) (4 weeks): MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). (met)
Result source: NCT05870540
VLS-01
Developed by AtaiBeckley Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Treatment-Resistant Depression
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
VLS-01: no structured comparison results are available for Treatment-Resistant Depression.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
BPL-003 (mebufotenin benzoate)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPL-003 (mebufotenin benzoate)'s landscape · VLS-01's landscape